The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis

<b>Background</b>: Depression is associated with worse outcomes in persons living with HIV/AIDS and has a prevalence more than three times as high as in the general population. Despite this, there are few randomized studies of antidepressants in HIV-infected Africans.

<b>Methods: </b>We enrolled 460 HIV-infected Africans with cryptococcal meningitis into a randomized clinical trial of adjunctive sertraline vs placebo (2015-2017). We screened for clinical depression using the Center for Epidemiologic Studies Depression Scale (CES-D) at one and three months after meningitis diagnosis and initiation of treatment. We evaluated the relationship between sertraline and depression, as well as associations with persistent depression, at three months.

<b>Results: </b>At one- and three-months post meningitis diagnosis, 62% (108/174) and 44% (74/169) of all subjects had depression (CES&gt;15), respectively. At three months, sertraline-treated subjects were non-significantly more likely to be depressed than placebo-treated subjects (64% vs 37%, p=0.09) but were significantly less likely to have severe depression (CES&gt;26) (OR 0.335; 95%CI, 0.130-0.865). Of those with depression at one month, sertraline-treated subjects were less likely than placebo-treated subjects to be depressed at three months (p=0.05). Sertraline was the only factor we found significant in predicting persistent depression at three months among those who had depression at one month.

<b>Conclusions: </b>Depression is highly prevalent in HIV-infected persons who have survived cryptococcal meningitis. We found that sertraline is associated with a modest reduction in depression in those with depression at baseline and a significant reduction in severe depression.